Inhibrx Biosciences to Host Live Webcast for Clinical Update
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy INBX?
Source: PRnewswire
- Live Clinical Update: Inhibrx Biosciences will host a live webcast on April 21, 2026, at 1:30 PM PT to provide a clinical update on its Phase 1/2 study evaluating ozekibart (INBRX-109) in combination with FOLFIRI for patients with locally advanced or metastatic colorectal cancer, which is expected to attract investor interest.
- FDA Designation for ozekibart: Ozekibart, a tetravalent death receptor 5 (DR5) agonist antibody, has received Fast Track designation and orphan drug status from the FDA, highlighting its potential in treating metastatic or unresectable conventional chondrosarcoma, marking its significance in oncology.
- Significant Clinical Trial Results: The ChonDRAgon study demonstrated that ozekibart reduced the risk of disease progression or death by 52% (HR 0.479, P<0.0001) compared to placebo, with median progression-free survival increasing from 2.66 months to 5.52 months, making it the first investigational therapy to show significant PFS benefits in this indication.
- Multiple Indication Research: Inhibrx is also conducting Phase 1/2 trials of ozekibart in colorectal cancer and Ewing sarcoma, showcasing its potential across various tumor types and further solidifying the company's strategic position in the biopharmaceutical sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INBX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INBX
About INBX
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates. The Company utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary protein engineering platforms. Its clinical pipeline of therapeutic candidates includes ozekibart (INBRX-109) and INBRX-106. INBRX-109 is a tetravalent agonist of death receptor 5 (DR5) that it designed with its proprietary single domain antibody (sdAb) platform to drive cancer-selective programmed cell death and to maximize potency while minimizing on-target liver toxicity arising from hepatocyte apoptosis. INBRX-106 is a hexavalent OX40 agonist which is being investigated as a single agent and in combination with KEYTRUDA (pembrolizumab), a PD-1 blocking checkpoint inhibitor, in patients with locally advanced or metastatic solid tumors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Inhibrx to Host Live Webcast for Clinical Update
- Live Clinical Update: Inhibrx will host a live webcast on April 21, 2026, at 1:30 p.m. PT to provide a clinical update on ozekibart (INBRX-109) in combination with FOLFIRI for patients with locally advanced or metastatic colorectal cancer, aiming to engage investor interest in its research progress.
- FDA Fast Track Designation: Ozekibart received FDA Fast Track designation in January 2021 for treating patients with metastatic or unresectable conventional chondrosarcoma, highlighting its potential in oncology and possibly opening new market opportunities for the company.
- Clinical Trial Success: The ChonDRAgon study demonstrated a 52% reduction in the risk of disease progression or death for ozekibart compared to placebo (HR 0.479), with median progression-free survival increasing from 2.66 months to 5.52 months, marking a significant breakthrough in chondrosarcoma treatment.
- Multiple Indications Research: Inhibrx is also investigating ozekibart in Phase 1/2 trials for colorectal cancer and Ewing sarcoma, showcasing the diversity of its product pipeline and future growth potential, thereby enhancing the company's competitiveness in the biopharmaceutical sector.
See More
Inhibrx Biosciences to Host Live Webcast for Clinical Update
- Live Clinical Update: Inhibrx Biosciences will host a live webcast on April 21, 2026, at 1:30 PM PT to provide a clinical update on its Phase 1/2 study evaluating ozekibart (INBRX-109) in combination with FOLFIRI for patients with locally advanced or metastatic colorectal cancer, which is expected to attract investor interest.
- FDA Designation for ozekibart: Ozekibart, a tetravalent death receptor 5 (DR5) agonist antibody, has received Fast Track designation and orphan drug status from the FDA, highlighting its potential in treating metastatic or unresectable conventional chondrosarcoma, marking its significance in oncology.
- Significant Clinical Trial Results: The ChonDRAgon study demonstrated that ozekibart reduced the risk of disease progression or death by 52% (HR 0.479, P<0.0001) compared to placebo, with median progression-free survival increasing from 2.66 months to 5.52 months, making it the first investigational therapy to show significant PFS benefits in this indication.
- Multiple Indication Research: Inhibrx is also conducting Phase 1/2 trials of ozekibart in colorectal cancer and Ewing sarcoma, showcasing its potential across various tumor types and further solidifying the company's strategic position in the biopharmaceutical sector.
See More
Inhibrx Biosciences Receives Buy Rating from Stifel
- Coverage Initiation: Stifel has initiated coverage on Inhibrx Biosciences (INBX) with a Buy recommendation and a $150 price target, reflecting strong confidence in the potential of its cancer drug development.
- Market Potential Assessment: Analyst Dara Azar estimates risk-unadjusted sales for ozekibart and INBRX-106 could reach $5.3B to $5.8B, indicating that the current stock price does not fully reflect the market value of these assets.
- Target Innovation: INBRX-106 is a hexavalent agonist targeting head and neck squamous cell carcinoma, while ozekibart targets colorectal cancer and a rare cancer called chondrosarcoma, showcasing its broad applicability in oncology.
- Investment Outlook: The analyst noted that the current investment case represents only the visible portion, with a potentially much larger upside tied to the broader utility of these assets and the platform that could significantly enhance peak sales estimates.
See More
Inhibrx Biosciences Reports 2025 Financial Results
- Financial Overview: As of December 31, 2025, Inhibrx reported cash and cash equivalents of $124.2 million, indicating a relatively healthy liquidity position post-transaction with Sanofi, despite facing a net loss of $140.1 million.
- R&D Expense Analysis: Inhibrx's R&D expenses reached $113.1 million in 2025, significantly down from $203.7 million in 2024, reflecting the company's strategic shift towards optimizing resource allocation in response to market challenges.
- Operating Loss Situation: The company reported an operating loss of $135 million in 2025, and while revenues increased, high operational costs continue to exert pressure on financial performance, impacting investor confidence.
- Future Outlook and Plans: Inhibrx plans to submit a Biologics License Application to the FDA in Q2 2026 and expects to announce clinical trial data for ozekibart and INBRX-106, which, if successful, could significantly enhance the company's market position.
See More
Inhibrx Biosciences Reports Q4 Earnings Miss
- Earnings Report Miss: Inhibrx Biosciences reported a Q4 GAAP EPS of -$2.11, missing expectations by $0.03, indicating ongoing challenges in profitability that could impact investor confidence.
- Cash Position: As of December 31, 2025, Inhibrx had cash and cash equivalents totaling $124.2 million, which, while providing some liquidity, raises concerns about the efficiency of fund utilization and future financing needs.
- Loan Agreement Amendment: On March 18, 2026, the company entered into the First Amendment to the Loan and Security Agreement with Oxford Finance, LLC, securing gross proceeds of $75 million, which will provide short-term funding support and alleviate financial pressure.
- Market Outlook: Despite financial challenges, Inhibrx is actively pursuing treatments for chondrosarcoma and other targeted indications, with future R&D advancements potentially offering new growth opportunities for the company.
See More
Inhibrx Biosciences Options Risk Analysis
- Options Selling Risk: Selling puts on Inhibrx Biosciences does not provide the same upside potential as owning shares, as the put seller only acquires shares if the contract is exercised, highlighting the inherent risks of options trading.
- Exercise Condition Analysis: The put seller will only own shares at a cost basis of $42.00 if Inhibrx's stock declines by 31.7% and the contract is exercised, illustrating the complexity and potential losses associated with exercising options.
- Annualized Yield: The only upside for the put seller comes from the premium collected, yielding an annualized return of 16.7%, indicating that the risk-reward balance must be carefully evaluated under current market conditions.
- Volatility Consideration: With a trailing twelve-month volatility of 95% for Inhibrx, combining this with fundamental analysis can assist investors in determining whether selling the $50 strike put represents a worthwhile risk to take.
See More
Inhibrx to Host Live Webcast for Clinical Update
- Live Clinical Update: Inhibrx will host a live webcast on April 21, 2026, at 1:30 p.m. PT to provide a clinical update on ozekibart (INBRX-109) in combination with FOLFIRI for patients with locally advanced or metastatic colorectal cancer, aiming to engage investor interest in its research progress.
- FDA Fast Track Designation: Ozekibart received FDA Fast Track designation in January 2021 for treating patients with metastatic or unresectable conventional chondrosarcoma, highlighting its potential in oncology and possibly opening new market opportunities for the company.
- Clinical Trial Success: The ChonDRAgon study demonstrated a 52% reduction in the risk of disease progression or death for ozekibart compared to placebo (HR 0.479), with median progression-free survival increasing from 2.66 months to 5.52 months, marking a significant breakthrough in chondrosarcoma treatment.
- Multiple Indications Research: Inhibrx is also investigating ozekibart in Phase 1/2 trials for colorectal cancer and Ewing sarcoma, showcasing the diversity of its product pipeline and future growth potential, thereby enhancing the company's competitiveness in the biopharmaceutical sector.
See More
Inhibrx Biosciences to Host Live Webcast for Clinical Update
- Live Clinical Update: Inhibrx Biosciences will host a live webcast on April 21, 2026, at 1:30 PM PT to provide a clinical update on its Phase 1/2 study evaluating ozekibart (INBRX-109) in combination with FOLFIRI for patients with locally advanced or metastatic colorectal cancer, which is expected to attract investor interest.
- FDA Designation for ozekibart: Ozekibart, a tetravalent death receptor 5 (DR5) agonist antibody, has received Fast Track designation and orphan drug status from the FDA, highlighting its potential in treating metastatic or unresectable conventional chondrosarcoma, marking its significance in oncology.
- Significant Clinical Trial Results: The ChonDRAgon study demonstrated that ozekibart reduced the risk of disease progression or death by 52% (HR 0.479, P<0.0001) compared to placebo, with median progression-free survival increasing from 2.66 months to 5.52 months, making it the first investigational therapy to show significant PFS benefits in this indication.
- Multiple Indication Research: Inhibrx is also conducting Phase 1/2 trials of ozekibart in colorectal cancer and Ewing sarcoma, showcasing its potential across various tumor types and further solidifying the company's strategic position in the biopharmaceutical sector.
See More
Inhibrx Biosciences Receives Buy Rating from Stifel
- Coverage Initiation: Stifel has initiated coverage on Inhibrx Biosciences (INBX) with a Buy recommendation and a $150 price target, reflecting strong confidence in the potential of its cancer drug development.
- Market Potential Assessment: Analyst Dara Azar estimates risk-unadjusted sales for ozekibart and INBRX-106 could reach $5.3B to $5.8B, indicating that the current stock price does not fully reflect the market value of these assets.
- Target Innovation: INBRX-106 is a hexavalent agonist targeting head and neck squamous cell carcinoma, while ozekibart targets colorectal cancer and a rare cancer called chondrosarcoma, showcasing its broad applicability in oncology.
- Investment Outlook: The analyst noted that the current investment case represents only the visible portion, with a potentially much larger upside tied to the broader utility of these assets and the platform that could significantly enhance peak sales estimates.
See More
Inhibrx Biosciences Reports 2025 Financial Results
- Financial Overview: As of December 31, 2025, Inhibrx reported cash and cash equivalents of $124.2 million, indicating a relatively healthy liquidity position post-transaction with Sanofi, despite facing a net loss of $140.1 million.
- R&D Expense Analysis: Inhibrx's R&D expenses reached $113.1 million in 2025, significantly down from $203.7 million in 2024, reflecting the company's strategic shift towards optimizing resource allocation in response to market challenges.
- Operating Loss Situation: The company reported an operating loss of $135 million in 2025, and while revenues increased, high operational costs continue to exert pressure on financial performance, impacting investor confidence.
- Future Outlook and Plans: Inhibrx plans to submit a Biologics License Application to the FDA in Q2 2026 and expects to announce clinical trial data for ozekibart and INBRX-106, which, if successful, could significantly enhance the company's market position.
See More
Inhibrx Biosciences Reports Q4 Earnings Miss
- Earnings Report Miss: Inhibrx Biosciences reported a Q4 GAAP EPS of -$2.11, missing expectations by $0.03, indicating ongoing challenges in profitability that could impact investor confidence.
- Cash Position: As of December 31, 2025, Inhibrx had cash and cash equivalents totaling $124.2 million, which, while providing some liquidity, raises concerns about the efficiency of fund utilization and future financing needs.
- Loan Agreement Amendment: On March 18, 2026, the company entered into the First Amendment to the Loan and Security Agreement with Oxford Finance, LLC, securing gross proceeds of $75 million, which will provide short-term funding support and alleviate financial pressure.
- Market Outlook: Despite financial challenges, Inhibrx is actively pursuing treatments for chondrosarcoma and other targeted indications, with future R&D advancements potentially offering new growth opportunities for the company.
See More
Inhibrx Biosciences Options Risk Analysis
- Options Selling Risk: Selling puts on Inhibrx Biosciences does not provide the same upside potential as owning shares, as the put seller only acquires shares if the contract is exercised, highlighting the inherent risks of options trading.
- Exercise Condition Analysis: The put seller will only own shares at a cost basis of $42.00 if Inhibrx's stock declines by 31.7% and the contract is exercised, illustrating the complexity and potential losses associated with exercising options.
- Annualized Yield: The only upside for the put seller comes from the premium collected, yielding an annualized return of 16.7%, indicating that the risk-reward balance must be carefully evaluated under current market conditions.
- Volatility Consideration: With a trailing twelve-month volatility of 95% for Inhibrx, combining this with fundamental analysis can assist investors in determining whether selling the $50 strike put represents a worthwhile risk to take.
See More
